16,510 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Bought by Erste Asset Management GmbH

Erste Asset Management GmbH purchased a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 16,510 shares of the biopharmaceutical company’s stock, valued at approximately $4,539,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of ALNY. TD Asset Management Inc grew its holdings in shares of Alnylam Pharmaceuticals by 6.0% during the second quarter. TD Asset Management Inc now owns 489,940 shares of the biopharmaceutical company’s stock valued at $119,055,000 after buying an additional 27,592 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Alnylam Pharmaceuticals by 3.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 487,348 shares of the biopharmaceutical company’s stock valued at $134,035,000 after purchasing an additional 16,756 shares during the last quarter. Avoro Capital Advisors LLC boosted its stake in Alnylam Pharmaceuticals by 33.3% during the 2nd quarter. Avoro Capital Advisors LLC now owns 400,000 shares of the biopharmaceutical company’s stock valued at $97,200,000 after purchasing an additional 100,000 shares during the last quarter. Swiss National Bank increased its holdings in Alnylam Pharmaceuticals by 0.3% during the 3rd quarter. Swiss National Bank now owns 375,400 shares of the biopharmaceutical company’s stock worth $103,246,000 after purchasing an additional 1,000 shares in the last quarter. Finally, Eagle Asset Management Inc. raised its stake in shares of Alnylam Pharmaceuticals by 25.7% in the third quarter. Eagle Asset Management Inc. now owns 309,589 shares of the biopharmaceutical company’s stock worth $85,889,000 after purchasing an additional 63,385 shares during the last quarter. Institutional investors own 92.97% of the company’s stock.

Insider Activity

In other news, CMO Pushkal Garg sold 1,682 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $422,148.36. Following the completion of the transaction, the chief marketing officer now directly owns 17,457 shares in the company, valued at approximately $4,381,357.86. This trade represents a 8.79 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Tolga Tanguler sold 1,469 shares of the stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $368,689.62. Following the completion of the sale, the executive vice president now owns 13,191 shares in the company, valued at $3,310,677.18. This represents a 10.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 8,370 shares of company stock worth $2,100,703. 1.50% of the stock is owned by corporate insiders.

Alnylam Pharmaceuticals Price Performance

ALNY opened at $253.01 on Tuesday. The company has a market capitalization of $32.63 billion, a price-to-earnings ratio of -96.57 and a beta of 0.39. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. The firm has a 50-day moving average price of $271.07 and a 200-day moving average price of $242.32. Alnylam Pharmaceuticals, Inc. has a twelve month low of $141.98 and a twelve month high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The company had revenue of $500.90 million for the quarter, compared to analyst estimates of $532.91 million. The company’s quarterly revenue was down 33.3% compared to the same quarter last year. During the same period last year, the company earned $1.15 EPS. Equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.21 EPS for the current year.

Analyst Upgrades and Downgrades

ALNY has been the subject of several recent research reports. Raymond James upped their price target on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an “outperform” rating in a report on Friday, November 1st. Chardan Capital reiterated a “buy” rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. Cantor Fitzgerald reissued a “neutral” rating and set a $220.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, October 11th. TD Cowen upped their price objective on shares of Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Finally, Canaccord Genuity Group lifted their target price on shares of Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the stock a “buy” rating in a research report on Friday, November 1st. One research analyst has rated the stock with a sell rating, six have issued a hold rating and eighteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $298.09.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.